Author

Anju Parthan

Observed names: A Parthan, A. Parthan

Institution: Corcept Therapeutics (United States)

Observed institutions: Harvard University, New Cross Hospital, Sanofi (France), Accuray (United States), Antwerp University Hospital, Alkermes (United States), Dana-Farber Cancer Institute, Optum (United States), Alexion Pharmaceuticals (United States), Corcept Therapeutics (United States), Health Economics and Outcomes Research (United Kingdom), FibroGen (United States), St. Mary's Hospital, Infraredx, Inc. (United States), The University of Texas at Austin

ORCID: 0000-0002-2357-9479

Observed ORCID: 0000-0002-2357-9479

OpenAlex ID: A5076341878

The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review

2011 · Claire Bombardier, Marco Barbieri, et al. · Annals of the Rheumatic Diseases · 111

Cost Effectiveness of Denosumab versus Oral Bisphosphonates for Postmenopausal Osteoporosis in the US

2013 · Anju Parthan, Morgan Kruse, et al. · Applied Health Economics and Health Policy · 79

Understanding the Symptom Burden and Impact of Myasthenia Gravis from the Patient’s Perspective: A Qualitative Study

2022 · Kristi Jackson, Anju Parthan, et al. · Neurology and Therapy · 72

PDF

Comparative Cost-Effectiveness of Stereotactic Body Radiation Therapy Versus Intensity-Modulated and Proton Radiation Therapy for Localized Prostate Cancer

2012 · Anju Parthan, Narin Pruttivarasin, et al. · Frontiers in Oncology · 71

PDF

Chronic low back pain: epidemiology, economic burden and patient-reported outcomes in the USA

2006 · Anju Parthan, Christopher J Evans, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 66

Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective

2015 · Stuart Silverman, Irene Agodoa, et al. · Journal of Osteoporosis · 37

PDF

Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma

2016 · Kelly Fust, Xiaoyan Li, et al. · PharmacoEconomics · 32

PDF

Denosumab: A cost-effective alternative for older men with osteoporosis from a Swedish payer perspective

2013 · A. Parthan, M. Kruse, et al. · Bone · 29

Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck

2009 · Anju Parthan, Marshall R. Posner, et al. · Head & Neck · 26

A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture

2017 · Claire E. O’Hanlon, Anju Parthan, et al. · Clinical Therapeutics · 22

PDF

Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States

2012 · Myrlene Sanon, Douglas C.A. Taylor, et al. · Journal of Medical Economics · 20

PDF

United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use

2024 · Ali A. Habib, Andrew J. Klink, et al. · Journal of Neurology · 17

Strategies to improve adherence with medications in chronic, ‘silent’ diseases representing high cardiovascular risk

2006 · Anju Parthan, Gábor Vincze, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 16

Cost Effectiveness of Targeted High-dose Atorvastatin Therapy Following Genotype Testing in Patients with Acute Coronary Syndrome

2013 · Anju Parthan, Kevin J. Leahy, et al. · PharmacoEconomics · 14

Cost per response analysis of strategies for chronic immune thrombocytopenia.

2018 · Kelly Fust, Anju Parthan, et al. · PubMed · 11

Economic and humanistic burden of fibromyalgia in the USA

2006 · Christopher J Evans, Anju Parthan, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 11

Burden of illness and costs in patients with myasthenia gravis currently receiving treatment in the United States

2023 · A. Parthan, M. Royston, et al. · Muscle & Nerve · 10

PDF

Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer

2014 · Kelly Fust, Xiaoyan Li, et al. · Gynecologic Oncology · 10

Health Care Utilization and Costs by Site of Service for Nonmetastatic Breast Cancer Patients Treated with Trastuzumab

2014 · Anju Parthan, Eduardo Santos, et al. · Journal of Managed Care Pharmacy · 8

PDF

CyberKnife for prostate cancer: Is it cost-effective?

2011 · A. Parthan, N. Pruttivarasin, et al. · Journal of Clinical Oncology · 8

Examination of the Relationship between Direct-to-Consumer Advertising Expenditure and Price

2005 · Radhika Anantharaman, Anju Parthan, et al. · Drug Information Journal · 7

PMS26 Cost-Effectiveness of Denosumab Versus Oral Bisphosphonates in the United States for Post-Menopausal Osteoporosis (PMO)

2012 · A. Parthan, M.M. Deflin, et al. · Value in Health · 6

US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization

2024 · Richard J. Nowak, Ali A. Habib, et al. · Drugs - Real World Outcomes · 5

PDF

Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models

2017 · Kelly Fust, Anju Parthan, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 5

Real-World Eculizumab Effectiveness on US Patient Outcomes in Myasthenia Gravis (ELEVATE): a Retrospective Chart Review (S41.010)

2022 · Ali A. Habib, Andrew Klink, et al. · Neurology · 4

Works count: 59

Citation count: 733

H-index: 14

I10-index: 18